Compare Crispr Therapeutics AG (CRSP) vs Global X Lithium & Battery Tech ETF (LIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Global X Lithium & Battery Tech ETF — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while Global X Lithium & Battery Tech ETF trades at $71.22. The key difference: Global X Lithium & Battery Tech ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | LIT | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $76.78 | $91.62 |
52-Week Low | $44.34 | $39.73 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
LIT trades at $70.24, down 2.88% today amid bearish technical signals, with moving averages indicating selling pressure. The stock has doubled over the past year, driven by strong EV and semiconductor demand. Recent news highlights global EV sales growth, particularly in Europe and China, supporting the lithium and battery technology sector. A dividend of $0.32 is scheduled for July 2026.
Outlook remains positive due to structural demand for lithium in energy storage and EVs, though risks include Chinese export controls and U.S. regulatory uncertainty. Analyst sentiment is mixed, with some highlighting momentum catalysts while technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →
